HRP20060326A2 - Combined pharmaceutical composition for the inhibition of the decline of cognitive functions - Google Patents
Combined pharmaceutical composition for the inhibition of the decline of cognitive functionsInfo
- Publication number
- HRP20060326A2 HRP20060326A2 HR20060326A HRP20060326A HRP20060326A2 HR P20060326 A2 HRP20060326 A2 HR P20060326A2 HR 20060326 A HR20060326 A HR 20060326A HR P20060326 A HRP20060326 A HR P20060326A HR P20060326 A2 HRP20060326 A2 HR P20060326A2
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- syndrome
- combined pharmaceutical
- mental disorder
- cognitive functions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 2
- 230000007423 decrease Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000006264 Korsakoff syndrome Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20060326A HRP20060326A2 (en) | 2004-03-12 | 2006-09-29 | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/HU2004/000022 WO2005087212A1 (en) | 2004-03-12 | 2004-03-12 | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
HR20060326A HRP20060326A2 (en) | 2004-03-12 | 2006-09-29 | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20060326A2 true HRP20060326A2 (en) | 2007-02-28 |
Family
ID=34957271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20060326A HRP20060326A2 (en) | 2004-03-12 | 2006-09-29 | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
Country Status (17)
Country | Link |
---|---|
US (1) | US20080021016A1 (pt) |
EP (1) | EP1727531A1 (pt) |
JP (1) | JP2007528892A (pt) |
CN (1) | CN1925849A (pt) |
AU (1) | AU2004317129A1 (pt) |
BR (1) | BRPI0418634A (pt) |
CA (1) | CA2559493A1 (pt) |
CZ (1) | CZ2006628A3 (pt) |
EA (1) | EA200601666A1 (pt) |
HR (1) | HRP20060326A2 (pt) |
IL (1) | IL177735A0 (pt) |
IS (1) | IS8547A (pt) |
MX (1) | MXPA06010384A (pt) |
NO (1) | NO20064644L (pt) |
RS (1) | RS20060505A (pt) |
SK (1) | SK50802006A3 (pt) |
WO (1) | WO2005087212A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2458983B1 (en) | 2009-07-31 | 2015-07-08 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
CN104173336B (zh) * | 2010-03-31 | 2018-02-02 | 重庆润泽医药有限公司 | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 |
JP2014511373A (ja) | 2011-02-02 | 2014-05-15 | コグニション セラピューティクス インク. | ウコン油から単離された化合物およびその使用方法 |
ITGE20110050A1 (it) * | 2011-04-29 | 2012-10-30 | Marco Zipoli | Alimento, in particolare una bevanda per l'alimentazione umana |
EP4023294A1 (en) | 2014-01-31 | 2022-07-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating alzheimer's disease |
BR112019023851A2 (pt) | 2017-05-15 | 2020-08-18 | Cognition Therapeutics, Inc. | compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
DE4136288A1 (de) * | 1991-11-04 | 1993-05-06 | Troponwerke Gmbh & Co Kg, 5000 Koeln, De | Kombination von calciumantagonisten mit cholinesterase-inhibitoren |
DE69618765T2 (de) * | 1995-02-15 | 2002-10-17 | Takeda Chemical Industries Ltd | Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta-amyloid-protein |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
GB9820489D0 (en) * | 1998-09-22 | 1998-11-11 | Steiger Malcolm J | Compounds for improved treatment of parkinson's disease |
US6426097B2 (en) * | 2000-01-28 | 2002-07-30 | Herbaceuticals Inc. | Herbal supplement for cognitive related impairment due to estrogen loss |
US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
WO2002053147A1 (es) * | 2000-12-29 | 2002-07-11 | Osmotica Corp. | Composicion farmaceutica para el tratamiento de la enfermedad cerebrovascular cognitiva |
HUP0103017A3 (en) * | 2001-07-18 | 2004-05-28 | Egis Gyogyszergyar Nyilvanosan | Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use |
EP1423127A1 (en) * | 2001-08-30 | 2004-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
DE20203244U1 (de) * | 2002-03-01 | 2002-05-23 | Meins Wolfgang | Pharmazeutische Zusammensetzung zur Prävention der Alzheimerdemenz |
CN100337628C (zh) * | 2002-08-07 | 2007-09-19 | 王登之 | 治疗痴呆症的尼莫地平口腔崩解片及其制备方法 |
-
2004
- 2004-03-12 WO PCT/HU2004/000022 patent/WO2005087212A1/en active Application Filing
- 2004-03-12 EA EA200601666A patent/EA200601666A1/ru unknown
- 2004-03-12 CN CNA2004800424056A patent/CN1925849A/zh active Pending
- 2004-03-12 RS YUP-2006/0505A patent/RS20060505A/sr unknown
- 2004-03-12 AU AU2004317129A patent/AU2004317129A1/en not_active Abandoned
- 2004-03-12 BR BRPI0418634-6A patent/BRPI0418634A/pt not_active IP Right Cessation
- 2004-03-12 MX MXPA06010384A patent/MXPA06010384A/es not_active Application Discontinuation
- 2004-03-12 JP JP2007502417A patent/JP2007528892A/ja active Pending
- 2004-03-12 CA CA002559493A patent/CA2559493A1/en not_active Abandoned
- 2004-03-12 US US10/592,461 patent/US20080021016A1/en not_active Abandoned
- 2004-03-12 CZ CZ20060628A patent/CZ2006628A3/cs unknown
- 2004-03-12 EP EP04720092A patent/EP1727531A1/en not_active Withdrawn
- 2004-03-12 SK SK5080-2006A patent/SK50802006A3/sk not_active Application Discontinuation
-
2006
- 2006-08-29 IL IL177735A patent/IL177735A0/en unknown
- 2006-09-29 HR HR20060326A patent/HRP20060326A2/xx not_active Application Discontinuation
- 2006-10-03 IS IS8547A patent/IS8547A/is unknown
- 2006-10-12 NO NO20064644A patent/NO20064644L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL177735A0 (en) | 2006-12-31 |
AU2004317129A1 (en) | 2005-09-22 |
BRPI0418634A (pt) | 2007-05-29 |
JP2007528892A (ja) | 2007-10-18 |
EA200601666A1 (ru) | 2007-04-27 |
CA2559493A1 (en) | 2005-09-22 |
CN1925849A (zh) | 2007-03-07 |
US20080021016A1 (en) | 2008-01-24 |
WO2005087212A1 (en) | 2005-09-22 |
IS8547A (is) | 2006-10-03 |
CZ2006628A3 (cs) | 2007-01-24 |
MXPA06010384A (es) | 2007-03-07 |
RS20060505A (en) | 2008-09-29 |
SK50802006A3 (sk) | 2007-03-01 |
EP1727531A1 (en) | 2006-12-06 |
NO20064644L (no) | 2006-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20060326A2 (en) | Combined pharmaceutical composition for the inhibition of the decline of cognitive functions | |
WO2001028996A3 (en) | Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases | |
EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
DE602005004286D1 (de) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs | |
BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
BR0210357A (pt) | Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus | |
HRP20040518A2 (en) | N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives | |
BR0314299A (pt) | Derivados de pirrolidona como inibidores de mao-b | |
UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
BR0312232A (pt) | Inibidores de caspases e seus usos | |
ATE415969T1 (de) | (s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel | |
ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
DE602005018972D1 (de) | 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren | |
MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
HUP0101224A2 (hu) | Neuraminidáz inhibitor hatású pirrolidinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
ATE401901T1 (de) | Antikrebs- und antivirale zusammensetzung | |
BRPI0211025B8 (pt) | um novo composto para o tratamento da impotência | |
HRP20070025A2 (en) | New pseudopolymorph of desloratadine formed with carbon dioxide | |
ES2284970T3 (es) | Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer. | |
HUP0302620A2 (hu) | Új cukorbetegség-ellenes kombinációs gyógyszerkészítmények és eljárás ezek előállítására | |
EA201000116A1 (ru) | Интраназальные фармацевтические композиции, содержащие янтарную кислоту | |
ATE247963T1 (de) | Medikament zur behandlung von glaukoma und ischämischer retinopathie | |
ATE296096T1 (de) | Erucamid-verbindungen zur behandlung und prävention von störungen des sekretorischen systems | |
MX2022008931A (es) | Composiciones farmaceuticas y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080220 Year of fee payment: 5 |
|
OBST | Application withdrawn |